The management of type 1 diabetes in Australian primary schools

Anne Marks1, Valerie Wilson, Jackie Crisp

  • 1Faculty of Health, University of Technology Sydney , Australia .

Insights

Management of type 1 diabetes in Australian primary schools is inconsistent. Insulin pump therapy improves school-based insulin access for children with type 1 diabetes, but not all receive recommended treatment.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Public Health

Background:

  • Type 1 diabetes management requires consistent insulin delivery.
  • School environments present unique challenges for managing chronic conditions like type 1 diabetes.
  • Parental perspectives are crucial for understanding the real-world application of diabetes care in educational settings.

Purpose of the Study:

  • To investigate the management of type 1 diabetes in Australian primary schools (Kindergarten-Year 2) from the parents' viewpoint.
  • To identify the types of diabetes treatments administered, the providers of care, and the locations of treatment delivery within schools.
  • To assess the consistency and adequacy of diabetes management in primary school settings.

Main Methods:

  • A cross-sectional, descriptive study design was employed.
  • Data were collected from 66 parents of children with type 1 diabetes attending Australian primary schools.
  • An online, self-administered questionnaire distributed via Survey Monkey and a dedicated Facebook page was used, with data analyzed using SPSSv21.

Main Results:

  • All children underwent blood glucose testing, with 49% self-testing.
  • 77% of children received insulin at school, with 34% self-administered and 53% delivered via insulin pump.
  • Children using insulin pumps (97%) and those able to self-administer insulin (93%) were more likely to receive school-based insulin compared to those using injections (55%) or unable to self-administer (65%).
  • 81% of treatments occurred in the classroom, with the remainder in administrative offices.

Conclusions:

  • Insulin administration in Australian primary schools is inconsistent, with not all children receiving recommended treatments.
  • Insulin pump therapy is associated with increased access to diabetes treatment at school.
  • Further improvements are needed to ensure consistent and adequate type 1 diabetes management in primary school settings.
Abstract

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.4K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.8K
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
40
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
57